JTE-907
Legal status
Legal status
Identifiers
  • N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.209.196
Chemical and physical data
FormulaC24H26N2O6
Molar mass438.472 g·mol−1
3D model (JSmol)
  • c4c3OCOc3ccc4CNC(=O)c(cc2ccc1OC)c(=O)[nH]c2c1OCCCCC
  • InChI=1S/C24H26N2O6/c1-3-4-5-10-30-22-19(29-2)9-7-16-12-17(24(28)26-21(16)22)23(27)25-13-15-6-8-18-20(11-15)32-14-31-18/h6-9,11-12H,3-5,10,13-14H2,1-2H3,(H,25,27)(H,26,28)
  • Key:GRAJFFFXJYFVOC-UHFFFAOYSA-N
  (verify)

JTE-907 is a drug used in scientific research that acts as a selective CB2 inverse agonist.[1][2] It has antiinflammatory effects in animal studies,[3] thought to be mediated by an interaction between the CB2 receptor and IgE.[4]

See also

References

  1. ↑ Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (February 2001). "In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor". The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 420–5. PMID 11160626.
  2. ↑ Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T (March 2006). "Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists". Journal of Medicinal Chemistry. 49 (6): 2022–7. doi:10.1021/jm050879z. PMID 16539390.
  3. ↑ Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H (September 2005). "Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice". European Journal of Pharmacology. 520 (1–3): 164–71. doi:10.1016/j.ejphar.2005.08.013. PMID 16153638.
  4. ↑ Ueda Y, Miyagawa N, Wakitani K (January 2007). "Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice". Life Sciences. 80 (5): 414–9. doi:10.1016/j.lfs.2006.09.026. PMID 17055000.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.